<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00093769</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000390235</org_study_id>
    <secondary_id>UCLA-0401054-01</secondary_id>
    <secondary_id>MILLENNIUM-M34103-061</secondary_id>
    <nct_id>NCT00093769</nct_id>
  </id_info>
  <brief_title>Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase II Study of VELCADE With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary&#xD;
      for their growth. Monoclonal antibodies such as rituximab can locate cancer cells and either&#xD;
      kill them or deliver tumor-killing substances to them without harming normal cells. Giving&#xD;
      bortezomib together with rituximab may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well giving bortezomib together with&#xD;
      rituximab works in treating patients with relapsed or refractory non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate (complete response [CR], CR-unconfirmed [CRu], and partial&#xD;
           response [PR]) in patients with relapsed or refractory indolent B-cell non-Hodgkin's&#xD;
           lymphoma treated with bortezomib and rituximab.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the response rate (CR, CRu, and PR) at the first disease response evaluation&#xD;
           in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the overall CR rate (CR and CRu) in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the time to progression in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the duration of response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the time to best response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified&#xD;
      according to participating center, Karnofsky performance status (&lt; 70% vs ≥ 70%), lactic&#xD;
      dehydrogenase level (normal vs &gt; upper limit of normal), age (18 to 60 years vs &gt; 60 years),&#xD;
      and lymphoma subtype (follicular vs marginal zone). Patients are randomized to 1 of 2&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients&#xD;
           also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2&#xD;
           only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22.&#xD;
           Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment&#xD;
           repeats every 35 days for up to 3 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Patients in either arm may crossover to the other arm if treatment is found to be&#xD;
      ineffective.&#xD;
&#xD;
      Patients are followed at 30 days and then every 12 weeks thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24-66 patients (12-33 per treatment arm) will be accrued for&#xD;
      this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (complete response [CR], CR-unconfirmed [CRu], and partial response [PR])</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (CR, CRu, and PR) at the first disease response evaluation</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall CR rate (CR and CRu)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>bortezomib + rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Patients in either arm may crossover to the other arm if treatment is found to be ineffective.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib + rituximab</intervention_name>
    <description>Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Patients in either arm may crossover to the other arm if treatment is found to be ineffective.</description>
    <arm_group_label>bortezomib + rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of indolent B-cell non-Hodgkin's lymphoma of 1 of the following subtypes:&#xD;
&#xD;
               -  Follicular (grade 1, 2, or 3)&#xD;
&#xD;
               -  Marginal zone (extranodal, nodal, or splenic)&#xD;
&#xD;
          -  CD20-positive disease&#xD;
&#xD;
          -  Relapsed or progressive disease after prior anti-neoplastic therapy, as indicated by 1&#xD;
             of the following:&#xD;
&#xD;
               -  New lesions&#xD;
&#xD;
               -  Objective evidence of progression of existing lesions&#xD;
&#xD;
          -  Complete response ≥ 6 months in duration after prior rituximab therapy* NOTE: *For&#xD;
             patients who were previously treated with a regimen that included rituximab&#xD;
&#xD;
          -  At least 1 measurable lymph node mass &gt; 1.5 cm in 2 perpendicular dimensions that has&#xD;
             not been irradiated OR that has progressed since prior radiotherapy&#xD;
&#xD;
          -  No active CNS lymphoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 50-100% OR&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 2 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No known anaphylaxis or immunoglobulin E-mediated hypersensitivity to murine proteins&#xD;
             or to any component of rituximab, including polysorbate 80 and sodium citrate&#xD;
             dihydrate&#xD;
&#xD;
          -  No active systemic infection requiring treatment&#xD;
&#xD;
          -  No history of allergic reaction attributable to compounds containing boron or mannitol&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No peripheral neuropathy or neuropathic pain ≥ grade 2&#xD;
&#xD;
          -  No other malignancy within the past 5 years except completely resected basal cell or&#xD;
             squamous cell skin cancer or an in situ malignancy&#xD;
&#xD;
               -  Previously diagnosed prostate cancer allowed provided the following criteria are&#xD;
                  met:&#xD;
&#xD;
                    -  T1-2a, N0, M0 disease AND Gleason score ≤ 7 AND prostate specific antigen&#xD;
                       (PSA) ≤ 10 ng/mL before initial therapy&#xD;
&#xD;
                    -  Treated with definitive curative therapy (i.e., prostatectomy or&#xD;
                       radiotherapy) within the past 2 years&#xD;
&#xD;
                    -  No clinical evidence of prostate cancer AND undetectable PSA (for&#xD;
                       prostatectomy patients) or PSA &lt; 1 ng/mL (for patients who did not undergo&#xD;
                       prostatectomy)&#xD;
&#xD;
          -  No serious medical or psychiatric illness that would preclude study participation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 10 weeks since prior radioimmunoconjugates or toxin immunoconjugates (e.g.,&#xD;
             ibritumomab tiuxetan or iodine I 131 tositumomab)&#xD;
&#xD;
          -  More than 4 weeks since prior rituximab, alemtuzumab, or other unconjugated&#xD;
             therapeutic antibody&#xD;
&#xD;
          -  No concurrent prophylactic bone marrow growth factors (e.g., filgrastim [G-CSF],&#xD;
             sargramostim [GM-CSF], or epoetin alfa) during course 1 of study therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 6 weeks since prior nitrosoureas&#xD;
&#xD;
          -  No concurrent cisplatin&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent corticosteroids (e.g., dexamethasone) except prednisone ≤ 15 mg/day or&#xD;
             equivalent for adrenal insufficiency&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Biologic therapy&#xD;
&#xD;
          -  More than 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 2 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  No prior bortezomib&#xD;
&#xD;
          -  More than 3 weeks since prior antineoplastic therapy&#xD;
&#xD;
          -  More than 3 weeks since prior experimental therapy&#xD;
&#xD;
          -  No other concurrent antineoplastic therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
               -  Concurrent participation in a non-treatment study allowed provided it does not&#xD;
                  interfere with participation in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven De Vos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, Glenn M, Gregory SA, Holladay C, Zhang T, Boral AL. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol. 2009 Oct 20;27(30):5023-30. doi: 10.1200/JCO.2008.17.7980. Epub 2009 Sep 21.</citation>
    <PMID>19770386</PMID>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>October 6, 2004</study_first_submitted>
  <study_first_submitted_qc>October 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2004</study_first_posted>
  <last_update_submitted>October 3, 2012</last_update_submitted>
  <last_update_submitted_qc>October 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

